135 related articles for article (PubMed ID: 22356228)
1. K(v) 7 (KCNQ) channel openers normalize central 2-deoxyglucose uptake in a mouse model of mania and increase prefrontal cortical and hippocampal serine-9 phosphorylation levels of GSK3β.
Kristensen LV; Sandager-Nielsen K; Hansen HH
J Neurochem; 2012 May; 121(3):373-82. PubMed ID: 22356228
[TBL] [Abstract][Full Text] [Related]
2. Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania.
Redrobe JP; Nielsen AN
Behav Brain Res; 2009 Mar; 198(2):481-5. PubMed ID: 19162078
[TBL] [Abstract][Full Text] [Related]
3. Kv7 (KCNQ) channel openers induce hypothermia in the mouse.
Kristensen LV; Sandager-Nielsen K; Hansen HH
Neurosci Lett; 2011 Jan; 488(2):178-82. PubMed ID: 21087654
[TBL] [Abstract][Full Text] [Related]
4. Effect of the new antiepileptic drug retigabine in a rodent model of mania.
Dencker D; Dias R; Pedersen ML; Husum H
Epilepsy Behav; 2008 Jan; 12(1):49-53. PubMed ID: 18086455
[TBL] [Abstract][Full Text] [Related]
5. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine.
Hansen HH; Andreasen JT; Weikop P; Mirza N; Scheel-Krüger J; Mikkelsen JD
Eur J Pharmacol; 2007 Sep; 570(1-3):77-88. PubMed ID: 17628530
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of ICA-27243 on cloned K(V)7 channels.
Blom SM; Schmitt N; Jensen HS
Pharmacology; 2010; 86(3):174-81. PubMed ID: 20714208
[TBL] [Abstract][Full Text] [Related]
7. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder.
Dencker D; Husum H
Behav Brain Res; 2010 Feb; 207(1):78-83. PubMed ID: 19815032
[TBL] [Abstract][Full Text] [Related]
8. Indoleamine-2,3-dioxygenase-1 is a molecular target for the protective activity of mood stabilizers against mania-like behavior induced by d-amphetamine.
Tran HQ; Shin EJ; Saito K; Tran TV; Phan DH; Sharma N; Kim DW; Choi SY; Jeong JH; Jang CG; Cheong JH; Nabeshima T; Kim HC
Food Chem Toxicol; 2020 Feb; 136():110986. PubMed ID: 31760073
[TBL] [Abstract][Full Text] [Related]
9. The pan-Kv7 (KCNQ) Channel Opener Retigabine Inhibits Striatal Excitability by Direct Action on Striatal Neurons In Vivo.
Hansen HH; Weikop P; Mikkelsen MD; Rode F; Mikkelsen JD
Basic Clin Pharmacol Toxicol; 2017 Jan; 120(1):46-51. PubMed ID: 27377794
[TBL] [Abstract][Full Text] [Related]
10. KCNQ/Kv7 channel activator flupirtine protects against acute stress-induced impairments of spatial memory retrieval and hippocampal LTP in rats.
Li C; Huang P; Lu Q; Zhou M; Guo L; Xu X
Neuroscience; 2014 Nov; 280():19-30. PubMed ID: 25234320
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission.
Sotty F; Damgaard T; Montezinho LP; Mørk A; Olsen CK; Bundgaard C; Husum H
J Pharmacol Exp Ther; 2009 Mar; 328(3):951-62. PubMed ID: 19098162
[TBL] [Abstract][Full Text] [Related]
12. Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania.
Macêdo DS; de Lucena DF; Queiroz AI; Cordeiro RC; Araújo MM; Sousa FC; Vasconcelos SM; Hyphantis TN; Quevedo J; McIntyre RS; Carvalho AF
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():230-7. PubMed ID: 23333378
[TBL] [Abstract][Full Text] [Related]
13. Activation of peripheral KCNQ channels attenuates inflammatory pain.
Hayashi H; Iwata M; Tsuchimori N; Matsumoto T
Mol Pain; 2014 Feb; 10():15. PubMed ID: 24555569
[TBL] [Abstract][Full Text] [Related]
14. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity.
Yeung SY; Pucovský V; Moffatt JD; Saldanha L; Schwake M; Ohya S; Greenwood IA
Br J Pharmacol; 2007 Jul; 151(6):758-70. PubMed ID: 17519950
[TBL] [Abstract][Full Text] [Related]
15. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Padilla K; Wickenden AD; Gerlach AC; McCormack K
Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
[TBL] [Abstract][Full Text] [Related]
16. Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips.
Zagorchev P; Apostolova E; Kokova V; Peychev L
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):439-46. PubMed ID: 26815201
[TBL] [Abstract][Full Text] [Related]
17. Brain creatine kinase activity in an animal model of mania.
Streck EL; Amboni G; Scaini G; Di-Pietro PB; Rezin GT; Valvassori SS; Luz G; Kapczinski F; Quevedo J
Life Sci; 2008 Feb; 82(7-8):424-9. PubMed ID: 18191157
[TBL] [Abstract][Full Text] [Related]
18. The pharmacological effect of positive KCNQ (Kv7) modulators on dopamine release from striatal slices.
Jensen MM; Lange SC; Thomsen MS; Hansen HH; Mikkelsen JD
Basic Clin Pharmacol Toxicol; 2011 Nov; 109(5):339-42. PubMed ID: 21599837
[TBL] [Abstract][Full Text] [Related]
19. Memory and brain-derived neurotrophic factor after subchronic or chronic amphetamine treatment in an animal model of mania.
Fries GR; Valvassori SS; Bock H; Stertz L; Magalhães PV; Mariot E; Varela RB; Kauer-Sant'Anna M; Quevedo J; Kapczinski F; Saraiva-Pereira ML
J Psychiatr Res; 2015 Sep; 68():329-36. PubMed ID: 26026487
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ; Large CH; Sankar R
Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
